International archives of allergy and immunology · 1997
Defined epitopes: in vivo and in vitro studies using recombinant allergens.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chapman M D, Smith A M, Vailes L D, Arruda L K
Аннотация
BACKGROUND: The aim of the studies was to investigate the biologic activity of recombinant cockroach and mite allergens and their potential for use in diagnosis and treatment of allergic disease.
METHODS: Cockroach allergens Bla g 2, Bla g 4 and Bla g 5 and mite group 5 allergens were produced in bacterial expression vectors and used for immediate skin and serum IgE antibody tests.
RESULTS: The cockroach allergens showed very good skin test reactivity in allergic patients, giving positive reactions at 10(-2)-10(-5) microg/ml; controls were negative at 10(0) microg/ml. These reactions correlated with serum IgE antibody results. The prevalence of reactivity to group 5 mite allergens varied with exposure. There was a high prevalence (70%) of sensitization to Blomia tropicalis allergen, Blo t 5, among patients from Brazil and Singapore, whereas < 20% of patients from Charlottesville, US and Manchester, UK gave positive skin tests to Blo t 5 (p < 0.001).
CONCLUSIONS: The results show that recombinant allergens retain biologic activity and suggest that cocktails of two to four recombinant allergens could be used for diagnostic or therapeutic purposes. The phased introduction of recombinant allergens should improve the management of allergic disease.
METHODS: Cockroach allergens Bla g 2, Bla g 4 and Bla g 5 and mite group 5 allergens were produced in bacterial expression vectors and used for immediate skin and serum IgE antibody tests.
RESULTS: The cockroach allergens showed very good skin test reactivity in allergic patients, giving positive reactions at 10(-2)-10(-5) microg/ml; controls were negative at 10(0) microg/ml. These reactions correlated with serum IgE antibody results. The prevalence of reactivity to group 5 mite allergens varied with exposure. There was a high prevalence (70%) of sensitization to Blomia tropicalis allergen, Blo t 5, among patients from Brazil and Singapore, whereas < 20% of patients from Charlottesville, US and Manchester, UK gave positive skin tests to Blo t 5 (p < 0.001).
CONCLUSIONS: The results show that recombinant allergens retain biologic activity and suggest that cocktails of two to four recombinant allergens could be used for diagnostic or therapeutic purposes. The phased introduction of recombinant allergens should improve the management of allergic disease.